AP652A - Synergistic combinations of zidovudine, 1592U89 and 3tc or Ftc. - Google Patents

Synergistic combinations of zidovudine, 1592U89 and 3tc or Ftc. Download PDF

Info

Publication number: AP652A
Authority: AP; ARIPO
Prior art keywords: cis; amino; zidovudine; pyrimidin; purin
Prior art date: 1995-03-30

Application number

APAP/P/1997/001089A

Other languages

English (en)

Other versions

AP9701089A0 (en

Inventor

David Walter Barry

Clair Martha Heider St

Original Assignee

The Wellcome Foundation Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-30

Filing date

1996-03-28

Publication date

1998-06-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP652(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-03-30 Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en

1995-03-30 Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en

1996-03-28 Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd

1997-10-31 Publication of AP9701089A0 publication Critical patent/AP9701089A0/xx

1998-06-19 Application granted granted Critical

1998-06-19 Publication of AP652A publication Critical patent/AP652A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Immunology (AREA)
Oncology (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicinal Preparation (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Cephalosporin Compounds (AREA)

APAP/P/1997/001089A 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592U89 and 3tc or Ftc. AP652A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9506489.5A GB9506489D0 (en)	1995-03-30	1995-03-30	Antiviral combinations
GBGB9506490.3A GB9506490D0 (en)	1995-03-30	1995-03-30	Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en)	1995-03-30	1996-03-28	Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number	Publication Date
AP9701089A0 AP9701089A0 (en)	1997-10-31
AP652A true AP652A (en)	1998-06-19

Family

ID=26306774

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1997/001089A AP652A (en)	1995-03-30	1996-03-28	Synergistic combinations of zidovudine, 1592U89 and 3tc or Ftc.

Country Status (36)

Country	Link
US (1)	US6417191B1 (uk)
EP (1)	EP0817637B1 (uk)
JP (1)	JP2954357B2 (uk)
KR (1)	KR100542536B1 (uk)
CN (1)	CN1103593C (uk)
AP (1)	AP652A (uk)
AT (1)	ATE220551T1 (uk)
AU (1)	AU715213B2 (uk)
BR (3)	BR9607851B1 (uk)
CA (1)	CA2216634C (uk)
CZ (1)	CZ295940B6 (uk)
DE (3)	DE122005000029I2 (uk)
DK (1)	DK0817637T3 (uk)
EA (1)	EA000626B3 (uk)
EE (1)	EE04047B1 (uk)
ES (1)	ES2179193T3 (uk)
FR (1)	FR05C0022I2 (uk)
GE (1)	GEP20022647B (uk)
HK (1)	HK1009401A1 (uk)
HU (1)	HU224010B1 (uk)
IL (1)	IL117727A (uk)
LU (1)	LU91171I2 (uk)
MX (1)	MX9707316A (uk)
MY (1)	MY115461A (uk)
NL (1)	NL300195I2 (uk)
NO (2)	NO313787B1 (uk)
NZ (1)	NZ306419A (uk)
OA (1)	OA10616A (uk)
PL (1)	PL187085B1 (uk)
PT (1)	PT817637E (uk)
RO (1)	RO117995B1 (uk)
SI (1)	SI0817637T1 (uk)
SK (1)	SK283825B6 (uk)
TR (1)	TR199701074T1 (uk)
UA (1)	UA60293C2 (uk)
WO (1)	WO1996030025A1 (uk)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR199802704T2 (xx) *	1996-06-25	1999-03-22	Glaxo Group Limited	H�V tedavisinde Vx478, Zidov�din, FTC ve/veya 3TC i�eren kombinasyonlar�n kullan�m�.
US6113920A (en) *	1996-10-31	2000-09-05	Glaxo Wellcome Inc.	Pharmaceutical compositions
TW536403B (en) *	1997-03-24	2003-06-11	Glaxo Group Ltd	An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
AU769660B2 (en) *	1997-05-17	2004-01-29	Glaxo Group Limited	Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9709945D0 (en) *	1997-05-17	1997-07-09	Glaxo Group Ltd	A novel salt
WO1998052570A1 (en) *	1997-05-17	1998-11-26	Glaxo Group Limited	Antiviral combinations containing the carbocyclic nucleoside 1592u89
GB9809213D0 (en) *	1998-04-29	1998-07-01	Glaxo Group Ltd	Pharmaceutical compositions
US6875773B1 (en)	1998-05-29	2005-04-05	Ben M. Dunn	Combination therapy for treatment of FIV infection
CA2374198A1 (en) *	1998-05-29	1999-12-02	Maki Arai	Combination therapy for treatment of fiv infection
GB9820417D0 (en) *	1998-09-18	1998-11-11	Glaxo Group Ltd	Antiviral combinations
US6432966B2 (en)	1999-10-29	2002-08-13	Smithkline Beecham Corporation	Antiviral combinations
US7074417B2 (en) *	2000-10-13	2006-07-11	Advancis Pharmaceutical Corporation	Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) *	2001-05-11	2011-03-24	Cipla Medpro Pty Ltd	Pharmaceutical composition.
TW200403061A (en) *	2002-06-04	2004-03-01	Glaxo Group Ltd	Pharmaceutical compositions
AP2089A (en)	2003-01-14	2010-01-11	Gilead Sciences Inc	Compositions and methods for combination antiviraltherapy
JP4485520B2 (ja)	2003-03-24	2010-06-23	エフ．ホフマン−ラロシュアーゲー	逆転写酵素阻害剤としてのベンジル−ピリダジノン類
PL1692516T3 (pl)	2003-10-24	2011-05-31	Immunaid Pty Ltd	Sposób terapii
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
AU2006303368B2 (en)	2005-10-19	2011-05-26	F. Hoffmann-La Roche Ag	Non-Nucleoside Reverse Transcriptase Inhibitors
BRPI0720436A2 (pt)	2006-12-13	2014-01-07	Hoffmann La Roche	Inibidores de transcriptase reversa de não-nucleosídeo
DK2120878T3 (da) *	2007-02-09	2014-11-03	Alphapharm Pty Ltd	Doseringsform indeholdende to aktive farmaceutiske ingredienser i forskellige fysiske former
CA2763373C (en)	2009-05-27	2018-01-09	Immunaid Pty Ltd	Methods and systems for determining preferred times for administering therapy to treat diseases
EP3351249A1 (en)	2010-01-27	2018-07-25	VIIV Healthcare Company	Antiviral therapy
MX2016002560A (es)	2013-08-29	2016-10-26	Teva Pharma	Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
WO2015155673A1 (en)	2014-04-08	2015-10-15	Teva Pharmaceutical Industries Ltd	Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
EP3180349A4 (en)	2014-08-12	2018-08-22	Monash University	Lymph directing prodrugs
JP7118888B2 (ja)	2015-09-08	2022-08-16	モナッシュユニバーシティ	リンパ指向性プロドラッグ
CA3077739A1 (en) *	2017-08-29	2019-03-07	Puretech Lyt, Inc.	Lymphatic system-directing lipid prodrugs
US11883497B2 (en)	2017-08-29	2024-01-30	Puretech Lyt, Inc.	Lymphatic system-directing lipid prodrugs
US11608345B1 (en)	2017-12-19	2023-03-21	Puretech Lyt, Inc.	Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en)	2017-12-19	2022-04-19	Puretech Lyt, Inc.	Lipid prodrugs of mycophenolic acid and uses thereof
AU2021217172A1 (en)	2020-02-05	2022-09-22	Monash University	Lipid prodrugs of neurosteroids

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992015309A1 (en) *	1991-03-06	1992-09-17	The Wellcome Foundation Limited	Antiviral nucleoside combination
EP0513917A1 (en) *	1991-05-16	1992-11-19	Glaxo Group Limited	Antiviral combinations containing nucleoside analogs
WO1993023021A2 (en) *	1992-05-13	1993-11-25	The Wellcome Foundation Limited	Therapeutic combinations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4724232A (en) *	1985-03-16	1988-02-09	Burroughs Wellcome Co.	Treatment of human viral infections
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en)	1988-06-10	1992-06-16	Regents Of The University Of Minnesota	Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) *	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
US5204466A (en)	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en)	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
US5723490A (en)	1992-09-08	1998-03-03	Vertex Pharmaceuticals Incorporated	THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en)	1994-08-26	1994-10-19	Wellcome Found	A novel salt
US5869461A (en)	1995-03-16	1999-02-09	Yale University	Reducing toxicity of L-nucleosides with D-nucleosides
TR199802704T2 (xx)	1996-06-25	1999-03-22	Glaxo Group Limited	H�V tedavisinde Vx478, Zidov�din, FTC ve/veya 3TC i�eren kombinasyonlar�n kullan�m�.
BR9709951A (pt)	1996-06-25	1999-08-10	Glaxo Group Ltd	Combinação formulação farmacêutica processo de tratamento de uma infecção por hiv em um animal infectado uso de éster de tetraidro-3-furilanila do ácido 3s[3r(1r,2s)]-[3-[[4-amino-enil)sulfonil](2-metilpropil]-2-hiroxi-1-fenilmetil)propil]-carbânico, zidovudino,e (1s,4r)-cis-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]-2-ciclopenteno-1-metanol e pacote para paciente
DE10226522A1 (de) *	2002-06-14	2003-12-24	Degussa	Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

1996
- 1996-03-27 MY MYPI96001152A patent/MY115461A/en unknown
- 1996-03-28 ES ES96911953T patent/ES2179193T3/es not_active Expired - Lifetime
- 1996-03-28 DE DE1996622386 patent/DE122005000029I2/de active Active
- 1996-03-28 CA CA002216634A patent/CA2216634C/en not_active Expired - Lifetime
- 1996-03-28 CN CN96194050A patent/CN1103593C/zh not_active Expired - Lifetime
- 1996-03-28 BR BRPI9607851-0A patent/BR9607851B1/pt active IP Right Grant
- 1996-03-28 SI SI9630494T patent/SI0817637T1/xx unknown
- 1996-03-28 DE DE69622386T patent/DE69622386T2/de not_active Expired - Lifetime
- 1996-03-28 GE GEAP19963898A patent/GEP20022647B/en unknown
- 1996-03-28 BR BRPI9607851A patent/BRPI9607851B8/pt unknown
- 1996-03-28 SK SK1295-97A patent/SK283825B6/sk not_active IP Right Cessation
- 1996-03-28 US US08/930,225 patent/US6417191B1/en not_active Expired - Lifetime
- 1996-03-28 HU HU9801571A patent/HU224010B1/hu active Protection Beyond IP Right Term
- 1996-03-28 PT PT96911953T patent/PT817637E/pt unknown
- 1996-03-28 RO RO97-01795A patent/RO117995B1/ro unknown
- 1996-03-28 EA EA199700203A patent/EA000626B3/ru not_active IP Right Cessation
- 1996-03-28 CZ CZ19973090A patent/CZ295940B6/cs not_active IP Right Cessation
- 1996-03-28 AU AU54972/96A patent/AU715213B2/en not_active Expired
- 1996-03-28 KR KR1019970706824A patent/KR100542536B1/ko not_active IP Right Cessation
- 1996-03-28 EP EP96911953A patent/EP0817637B1/en not_active Expired - Lifetime
- 1996-03-28 DK DK96911953T patent/DK0817637T3/da active
- 1996-03-28 JP JP8528931A patent/JP2954357B2/ja not_active Expired - Lifetime
- 1996-03-28 TR TR97/01074T patent/TR199701074T1/xx unknown
- 1996-03-28 NZ NZ306419A patent/NZ306419A/xx not_active IP Right Cessation
- 1996-03-28 EE EE9700240A patent/EE04047B1/xx not_active IP Right Cessation
- 1996-03-28 UA UA97094740A patent/UA60293C2/uk unknown
- 1996-03-28 AT AT96911953T patent/ATE220551T1/de active
- 1996-03-28 PL PL96322532A patent/PL187085B1/pl unknown
- 1996-03-28 MX MX9707316A patent/MX9707316A/es active IP Right Grant
- 1996-03-28 WO PCT/EP1996/001352 patent/WO1996030025A1/en active IP Right Grant
- 1996-03-28 AP APAP/P/1997/001089A patent/AP652A/en active
- 1996-03-28 DE DE200512000029 patent/DE122005000029I1/de active Pending
- 1996-03-28 BR BRPI9612992-1A patent/BRPI9612992B1/pt not_active IP Right Cessation
- 1996-03-29 IL IL11772796A patent/IL117727A/xx not_active IP Right Cessation
1997
- 1997-09-17 OA OA70075A patent/OA10616A/en unknown
- 1997-09-29 NO NO19974510A patent/NO313787B1/no not_active IP Right Cessation
1998
- 1998-09-04 HK HK98110458A patent/HK1009401A1/xx not_active IP Right Cessation
2005
- 2005-05-04 LU LU91171C patent/LU91171I2/fr unknown
- 2005-05-09 FR FR05C0022C patent/FR05C0022I2/fr active Active
- 2005-05-09 NL NL300195C patent/NL300195I2/nl unknown
- 2005-05-24 NO NO2005014C patent/NO2005014I2/no unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992015309A1 (en) *	1991-03-06	1992-09-17	The Wellcome Foundation Limited	Antiviral nucleoside combination
EP0513917A1 (en) *	1991-05-16	1992-11-19	Glaxo Group Limited	Antiviral combinations containing nucleoside analogs
WO1993023021A2 (en) *	1992-05-13	1993-11-25	The Wellcome Foundation Limited	Therapeutic combinations

Also Published As

Publication number	Publication date
SK283825B6 (sk)	2004-02-03
WO1996030025A1 (en)	1996-10-03
HU224010B1 (hu)	2005-04-28
CZ295940B6 (cs)	2005-12-14
EE04047B1 (et)	2003-06-16
DE69622386D1 (de)	2002-08-22
SI0817637T1 (en)	2002-10-31
PL187085B1 (pl)	2004-05-31
IL117727A (en)	1999-11-30
NL300195I2 (nl)	2005-11-01
AU5497296A (en)	1996-10-16
BR9607851B1 (pt)	2009-01-13
EP0817637B1 (en)	2002-07-17
NZ306419A (en)	2000-01-28
PT817637E (pt)	2002-11-29
CZ309097A3 (cs)	1998-05-13
BRPI9612992B1 (pt)	2020-08-04
OA10616A (en)	2001-03-15
EE9700240A (et)	1998-04-15
HK1009401A1 (en)	1999-09-10
NL300195I1 (nl)	2005-08-01
TR199701074T1 (xx)	1998-02-21
EA000626B1 (ru)	1999-12-29
NO2005014I1 (no)	2005-06-06
HUP9801571A2 (hu)	1999-01-28
RO117995B1 (ro)	2002-12-30
KR100542536B1 (ko)	2006-03-23
MX9707316A (es)	1997-11-29
BRPI9607851B8 (pt)	2019-11-05
DE122005000029I2 (de)	2006-04-27
MY115461A (en)	2003-06-30
CA2216634C (en)	2004-07-20
JPH10511682A (ja)	1998-11-10
AU715213B2 (en)	2000-01-20
US6417191B1 (en)	2002-07-09
SK129597A3 (en)	1998-07-08
ES2179193T3 (es)	2003-01-16
NO974510L (no)	1997-09-29
EA199700203A1 (ru)	1998-02-26
NO313787B1 (no)	2002-12-02
EA000626B3 (ru)	2016-04-29
JP2954357B2 (ja)	1999-09-27
AP9701089A0 (en)	1997-10-31
NO2005014I2 (no)	2008-02-11
DK0817637T3 (da)	2002-11-11
PL322532A1 (en)	1998-02-02
LU91171I2 (fr)	2005-07-04
NO974510D0 (no)	1997-09-29
FR05C0022I2 (uk)	2005-10-21
IL117727A0 (en)	1996-07-23
BR9607851A (pt)	1998-07-21
UA60293C2 (uk)	2003-10-15
FR05C0022I1 (uk)	2005-06-10
EP0817637A1 (en)	1998-01-14
DE69622386T2 (de)	2003-02-13
CN1103593C (zh)	2003-03-26
CA2216634A1 (en)	1996-10-03
KR19980703420A (ko)	1998-11-05
GEP20022647B (en)	2002-03-25
CN1185110A (zh)	1998-06-17
DE122005000029I1 (de)	2005-10-06
ATE220551T1 (de)	2002-08-15
HUP9801571A3 (en)	2001-04-28
LU91171I9 (uk)	2018-12-28

Publication	Publication Date	Title
AP652A (en)	1998-06-19	Synergistic combinations of zidovudine, 1592U89 and 3tc or Ftc.
AU727983B2 (en)	2001-01-04	Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatment of HIV
EP1113802B1 (en)	2004-06-30	Antiviral combinations of lamivudine and adefovir
US6486136B1 (en)	2002-11-26	Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV
US6432966B2 (en)	2002-08-13	Antiviral combinations
EP1113803A1 (en)	2001-07-11	Antiviral combinations comprising lamivudine and abacavir
WO2000018383A2 (en)	2000-04-06	Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
AU8017298A (en)	1998-12-11	Antiviral combinations containing the carbocyclic nucleoside 1592u89
MXPA98010386A (en)	2000-08-01	Combinations that include vx478, zidovudina and / or 1592u89 for use in the treatment of